State Street SPDR S&P Biotech 

$127.48
306
+$4.09+3.31% Today

Statistics

Day High
127.48
Day Low
126.02
52W High
-
52W Low
-
Volume
89,533
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
0.29%
Dividend
0.37

Upcoming

Dividends

0.29%Dividend Yield
Dec 25
$0.41
Sep 25
$0.03
Jun 25
$0.01
Mar 25
$0.01
Dec 24
$0
10Y Growth
8.91%
5Y Growth
55.08%
3Y Growth
179.12%
1Y Growth
-19.52%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XBI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
iShares Biotechnology
IBB
Mkt Cap0
iShares Nasdaq Biotechnology ETF is a direct competitor, focusing on biotechnology and pharmaceuticals listed on the NASDAQ, similar to XBI's focus on the biotech sector.
VanEck Biotech
BBH
Mkt Cap0
VanEck Vectors Biotech ETF specifically targets the biotech industry, making it a close competitor to XBI with a focus on large-cap biotech companies.
First Trust NYSE Arca Biotechnology Index Fund
FBT
Mkt Cap0
First Trust NYSE Arca Biotechnology Index Fund is another biotech-focused ETF, competing with XBI by investing in companies across various market caps in the biotech sector.
Invesco Biotechnology & Genome
PBE
Mkt Cap0
Invesco Dynamic Biotechnology & Genome ETF competes with XBI by investing in biotech and genome companies, offering a dynamic approach to the biotech industry.
ALPS Medical Breakthroughs
SBIO
Mkt Cap0
ALPS Medical Breakthroughs ETF focuses on small- and mid-cap companies in the biotech and pharmaceutical sectors, competing with XBI's broader biotech focus.
Direxion Daily S&P Biotech Bull 3X Shares
LABU
Mkt Cap0
Direxion Daily S&P Biotech Bull 3X Shares offers leveraged exposure to the biotechnology sector, competing with XBI by targeting similar companies but with a leveraged approach.
Direxion Daily S&P Biotech Bear 3X Shares
LABD
Mkt Cap0
Direxion Daily S&P Biotech Bear 3X Shares is the inverse of LABU, offering leveraged inverse exposure to the biotech sector, and competes with XBI by targeting investors looking for inverse biotech exposure.
Virtus LifeSci Biotech Products
BBP
Mkt Cap0
Virtus LifeSci Biotech Products ETF competes with XBI by focusing on companies with one or more drugs in Phase II or Phase III FDA clinical trials, targeting a specific niche within the biotech sector.
Virtus LifeSci Biotech Clinical Trials
BBC
Mkt Cap0
Virtus LifeSci Biotech Clinical Trials ETF is similar to BBP but focuses on companies in clinical trials, making it a competitor to XBI by targeting a specific investment strategy within the biotech industry.

About

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Show more...
CEO
Country
US
ISIN
US78464A8707

Listings

0 Comments

Share your thoughts

FAQ

What is State Street SPDR S&P Biotech stock price today?
The current price of XBI.BOATS is $127.48 USD — it has increased by +3.31% in the past 24 hours. Watch State Street SPDR S&P Biotech stock price performance more closely on the chart.
What is State Street SPDR S&P Biotech stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange State Street SPDR S&P Biotech stocks are traded under the ticker XBI.BOATS.
Does State Street SPDR S&P Biotech pay dividends?
Yes, XBI.BOATS dividends are paid quarterly. The last dividend per share was 0.41 USD. As of today, Dividend Yield (FWD)% is 0.29%.
When did State Street SPDR S&P Biotech complete a stock split?
State Street SPDR S&P Biotech has not had any recent stock splits.